Odronextamab is used for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma, including in patients who are refractory to chimeric antigen receptor T-cell (CAR-T) therapy; it demonstrates durable and complete responses by engaging CD3 on T cells and CD20 on B cells.